Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat

The biotechnology industry had a rough first-half 2024 after a decent performance in 2023. The majority of biotech players do not generate enough revenues to fund their operations and are dependent on external funds. A biotech company starts generating revenues following a successful FDA approval and the launch of any drug. Under this circumstance, a high interest rate regime is detrimental to the biotech industry. The primary reason for the industry's weak performance year to date is that the Fed refrained ...